-
Company Insights
Innovation and Patenting activity of Cantargia AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cantargia AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Solid Tumor Drug Details: Nadunolimab (CAN-04) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Colon Cancer Drug Details: Nadunolimab (CAN-04) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Metastatic Colorectal Cancer Drug Details: Nadunolimab (CAN-04) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Gallbladder Cancer Drug Details: Nadunolimab (CAN-04) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Bladder Cancer Drug Details: Nadunolimab (CAN-04) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Pancreatic Ductal Adenocarcinoma Drug Details: Nadunolimab (CAN-04) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Metastatic Biliary Tract Cancer Drug Details: Nadunolimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Extrahepatic Bile Duct Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Extrahepatic Bile Duct Cancer Drug Details: Nadunolimab...